Reported 23 days ago
Analyst Michael Yee from Jefferies emphasizes Gilead’s potential for growth due to its new HIV prevention drug which recently passed a second Phase 3 study. Despite its stagnant stock performance over the years, Yee argues that this innovative biannual injection could capture a significant market share, transforming Gilead into a strong biotech player amidst the rising popularity of GLP-1 weight-loss drugs.
Source: YAHOO